Array
SAVE THE DATE:
CDK4/6 inhibition in early breast cancer – Recent data and controversies?
Date: | 08.11.2023 |
Start/End: | 05.30 – 07.00 pm (CET) |
Location: | virtual |
29.08.2023
In this international ABCSG webinar that is co-sponsored by EliLilly and Novartis, we welcome internationally renowned breast cancer experts Eva Carrasco from Spain and Stephen Johnston from UK – we are excited that they will present and discuss the most recent data of the pivotal adjuvant CDK4/6 studies monarchE and NATALEE for us.
The aim of the webinar is not only to learn about the clinical trial results, the adjuvant treatment options with CDK4/6 inhibitors, and the clinical consequences for everyday practice, but also to discuss the related controversies and current and future implications for early breast cancer patients and healthcare systems.
A discussion panel including ABCSG-experts Marija Balic, Gabriel Rinnerthaler, Rupert Bartsch, and Christian Singer will interpret the data together with our distinguished guest speakers – ABCSG President Michael Gnant will host the webinar, and lead through the Q&A from the audience.
Pre-registration is closed.
More posts on the topic:
CDK4/6 Inhibitors
Share on